FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947736019> ?p ?o ?g. }

• W2947736019 endingPage "10046" @default.
• W2947736019 startingPage "10046" @default.
• W2947736019 abstract "10046 Background: ONC201 is the first DRD2 antagonist for clinical oncology. The recommended phase 2 dose (RP2D) of 625mg ONC201 orally once a week has been established in adult patients. ONC201 efficacy has been shown in high-grade glioma preclinical models and radiographic regressions with single agent ONC201 have been reported in adult recurrent H3 K27M-mutant glioma patients. We report results from the first Phase I pediatric clinical trial of ONC201. Methods: This multicenter, open-label, dose-escalation and dose-expansion clinical trial (NCT03416530) determined the RP2D of ONC201 in pediatric H3 K27M-mutant glioma patients as a single agent. ONC201 was orally administered once a week and scaled by body weight. Dose escalation was performed by a 3 + 3 design beginning with one 125mg capsule less than the adult RP2D equivalent. Three patients were treated at the starting dose and 19 were treated at the adult RP2D equivalent. Results: The primary endpoint was achieved by establishing the safety of the adult RP2D scaled by body weight to pediatric patients. Twenty-two patients with a median age of 9 (range 3-18) years old who received at least prior radiation have been treated with ONC201: 15 with diffuse intrinsic pontine glioma (DIPG) (4 recurrent; 11 not recurrent) and 7 with non-DIPG H3 K27M-mutant glioma (all not recurrent). As of February 5, 2019, patients have received a median of 18 ONC201 doses (range 3-41) without instance of dose-limiting toxicity. Pharmacokinetic profiles were comparable to those observed in adults (Cmax ~2.1ug/mL; AUC ~2.3hr*ug/mL) and exposure was similar across body weights. Nine of 22 patients remain on therapy, 13 have discontinued due to progression, and 4 off-study patients are alive with a median follow up of 5.8 months. Five of the 11 (45%) DIPG patients who initiated ONC201 following radiation, but prior to recurrence, remain on therapy (median 7.4 months; range 4.4-9.6): median PFS is 4.4 months from initiation of ONC201 and 9.7 months from diagnosis; 7 of 11 (64%) patients are alive with median follow up of 11.8 months from diagnosis. Conclusions: ONC201 was well tolerated and achieved therapeutic exposure in pediatric H3 K27M-mutant glioma patients at the adult RP2D scaled by body weight. Further investigation of first-line ONC201 to treat H3 K27M-mutant glioma and/or DIPG is ongoing. Clinical trial information: NCT03416530." @default.
• W2947736019 created "2019-06-07" @default.
• W2947736019 creator A5001293585 @default.
• W2947736019 creator A5002908831 @default.
• W2947736019 creator A5006048639 @default.
• W2947736019 creator A5008547275 @default.
• W2947736019 creator A5024356241 @default.
• W2947736019 creator A5031795097 @default.
• W2947736019 creator A5036916387 @default.
• W2947736019 creator A5037362995 @default.
• W2947736019 creator A5037614274 @default.
• W2947736019 creator A5038295657 @default.
• W2947736019 creator A5045679809 @default.
• W2947736019 creator A5054513201 @default.
• W2947736019 creator A5055443333 @default.
• W2947736019 creator A5061250825 @default.
• W2947736019 creator A5083585208 @default.
• W2947736019 date "2019-05-20" @default.
• W2947736019 modified "2023-10-16" @default.
• W2947736019 title "ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma." @default.
• W2947736019 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.10046" @default.
• W2947736019 hasPublicationYear "2019" @default.
• W2947736019 type Work @default.
• W2947736019 sameAs 2947736019 @default.
• W2947736019 citedByCount "6" @default.
• W2947736019 countsByYear W29477360192019 @default.
• W2947736019 countsByYear W29477360192020 @default.
• W2947736019 countsByYear W29477360192022 @default.
• W2947736019 countsByYear W29477360192023 @default.
• W2947736019 crossrefType "journal-article" @default.
• W2947736019 hasAuthorship W2947736019A5001293585 @default.
• W2947736019 hasAuthorship W2947736019A5002908831 @default.
• W2947736019 hasAuthorship W2947736019A5006048639 @default.
• W2947736019 hasAuthorship W2947736019A5008547275 @default.
• W2947736019 hasAuthorship W2947736019A5024356241 @default.
• W2947736019 hasAuthorship W2947736019A5031795097 @default.
• W2947736019 hasAuthorship W2947736019A5036916387 @default.
• W2947736019 hasAuthorship W2947736019A5037362995 @default.
• W2947736019 hasAuthorship W2947736019A5037614274 @default.
• W2947736019 hasAuthorship W2947736019A5038295657 @default.
• W2947736019 hasAuthorship W2947736019A5045679809 @default.
• W2947736019 hasAuthorship W2947736019A5054513201 @default.
• W2947736019 hasAuthorship W2947736019A5055443333 @default.
• W2947736019 hasAuthorship W2947736019A5061250825 @default.
• W2947736019 hasAuthorship W2947736019A5083585208 @default.
• W2947736019 hasConcept C112705442 @default.
• W2947736019 hasConcept C126322002 @default.
• W2947736019 hasConcept C143998085 @default.
• W2947736019 hasConcept C197934379 @default.
• W2947736019 hasConcept C203092338 @default.
• W2947736019 hasConcept C22979827 @default.
• W2947736019 hasConcept C2778227246 @default.
• W2947736019 hasConcept C29730261 @default.
• W2947736019 hasConcept C502942594 @default.
• W2947736019 hasConcept C535046627 @default.
• W2947736019 hasConcept C71924100 @default.
• W2947736019 hasConcept C90924648 @default.
• W2947736019 hasConceptScore W2947736019C112705442 @default.
• W2947736019 hasConceptScore W2947736019C126322002 @default.
• W2947736019 hasConceptScore W2947736019C143998085 @default.
• W2947736019 hasConceptScore W2947736019C197934379 @default.
• W2947736019 hasConceptScore W2947736019C203092338 @default.
• W2947736019 hasConceptScore W2947736019C22979827 @default.
• W2947736019 hasConceptScore W2947736019C2778227246 @default.
• W2947736019 hasConceptScore W2947736019C29730261 @default.
• W2947736019 hasConceptScore W2947736019C502942594 @default.
• W2947736019 hasConceptScore W2947736019C535046627 @default.
• W2947736019 hasConceptScore W2947736019C71924100 @default.
• W2947736019 hasConceptScore W2947736019C90924648 @default.
• W2947736019 hasIssue "15_suppl" @default.
• W2947736019 hasLocation W29477360191 @default.
• W2947736019 hasOpenAccess W2947736019 @default.
• W2947736019 hasPrimaryLocation W29477360191 @default.
• W2947736019 hasRelatedWork W1934912325 @default.
• W2947736019 hasRelatedWork W1991965294 @default.
• W2947736019 hasRelatedWork W2051764329 @default.
• W2947736019 hasRelatedWork W2074207917 @default.
• W2947736019 hasRelatedWork W2087813266 @default.
• W2947736019 hasRelatedWork W2362417726 @default.
• W2947736019 hasRelatedWork W2550800421 @default.
• W2947736019 hasRelatedWork W3089163820 @default.
• W2947736019 hasRelatedWork W4382011019 @default.
• W2947736019 hasRelatedWork W2109522985 @default.
• W2947736019 hasVolume "37" @default.
• W2947736019 isParatext "false" @default.
• W2947736019 isRetracted "false" @default.
• W2947736019 magId "2947736019" @default.
• W2947736019 workType "article" @default.